Key result
Heart failure management in cardiac amyloidosis relies on loop diuretics and mineralocorticoid receptor antagonists, as conventional neurohormonal antagonists are often poorly tolerated.
Why the study?
Spreading awareness about cardiac amyloidosis is crucial to facilitate earlier diagnosis and proper therapeutic interventions, addressing an estimated 2-year delay.
This review highlights the unique challenges of managing heart failure in cardiac amyloidosis, emphasizing that standard neurohormonal antagonists are often poorly tolerated and that treatment should focus on judicious diuresis and disease-modifying therapies like tafamidis.
May prompt earlier CA evaluation in HF; leaves open optimal awareness strategies for prognosis.
Cardiac amyloidosis (CA) can lead to progressive heart failure (HF) by depositing insoluble amyloid fibrils within the myocardial extracellular space, resulting in an infiltrative and restrictive cardiomyopathy. Although CA was previously perceived as rare and incurable, recent advances in diagnostics and emerging therapies have been changing this outlook. It is crucial to spread awareness about CA to facilitate earlier diagnosis and proper therapeutic interventions, enhancing patient prognosis and survival. Currently, there is an estimated delay of 2 years from [...]
No takes yet. Share an insight, caveat, or question.
Faria et al. (2024) conducted a review in Cardiac amyloidosis. Heart failure medications (diuretics, MRA, beta blockers, ACEI/ARB) was evaluated. Heart failure management in cardiac amyloidosis relies on loop diuretics and mineralocorticoid receptor antagonists, as conventional neurohormonal antagonists are often poorly tolerated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: